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19AID EFFECTIVENESS 2011: PROGRESS IN IMPLEMENTING THE PARIS DECLARATION © OECD 2012
CHAPTER 1: OVERVIEW OF FINDINGS
Table 1.1  To what extent have global targets been met?
P ris Declaration indicators and targets, 2010






-- No Targetc --
3
a
41% 85% Not met
4
% of technical co-operation implemented through co-ordinated programmes consistent 
a
57% 50% Met
b 48% 55% Not met
44% No Targetc --
6
Total number of parallel project implementation units (PIUs)b











45% 66% Not met
a
19% 40% Not met
% of country analytic work undertaken jointlya
66% Not met
11








countries, the sample size is indicated in brackets.































































































































































































































































































































































































































































































































































































































































Age	Group	 Percentage	 Male	 Female	
0-14	years	 42.7%	 257,340	 243,174	
15-24	years	 19.7%	 116,605	 114,203	
25-54	years	 29.3%	 166,048	 177,024	
55-64	years	 4.8%	 28,717	 27,011	
65	years	and	over	 3.6%	 20,428	 21,840	











































































































































































69.4	 90.8	 96.6	 111.7	 137.7	 146.3	 166.1	
Financing	from	
Petroleum	Fund	
414.5	 512.8	 663.7	 985.4	 1,016.8	 1,457.6	 1,282.9	
Borrowing	 0.0	 0.0	 0.0	 0.0	 43.1	 43.6	 51.0	
Estimated	ODA	 184.0	 221.0	 263.9	 283.9	 253.6	 203.4	 117.9	
Total	Annual	
Budget	































































Indicator	 2000	 2008	 2012	
Population	 830,100	 1,079,700	 1,187,200	




Infant	mortality	rate	 100	 75	 45	
Total	fertility	rate	 7.1	 6.5	 6	









HDI		 0.418	 0.547	 0.576	

























































































































































































































































































development approaches have now superseded this transitional aid instrument, but it has pro-
vided many lessons on delivery of sustainable interventions and opportunities for development
cooperation during protracted conflict.57
Another innovative example of transitional aid instruments is the recent launch of the Sudan
UNDP Recovery Fund, designed to expedite implementation of early recovery activities in
Southern Sudan. This aid mechanism is perceived as a means to accelerate the delivery of
essential services given the slow progression of the MDTF and includes a steering committee
of government and international representatives with governance arrangements independent
of the MDTF. Multi- year funds will be available, with a focus on support systems for delivery
of basic services such as monitoring and evaluation and fiscal management of funds. 
The World Bank’s Post-conflict and Licus Trust Funds (which are being replaced by a new
‘State and Peace-building’ Fund) are dedicated to capacity building of government administra-
 tions based on a systems approach, while moving away from fragmented approaches that cha-
racterize responses to crises.58 The funds are intended to complement other aid instruments
(e.g. MDTF) whereby technical assistance is provided to core government departments for
design and management of civil service structures.59
Mix and Sequencing of Aid Instruments
Figure 9 illustrates the aid instruments described above, set along the relief to development
continuum. All aid mechanisms used in the transition have their strengths and weaknesses
(see Annex 6 for further details).  


























































































































































































































































































































































0.68%	 2010	 <1.00%	 National	
survey	
Percentage	of	sex	workers	who	are	HIV	infected	 2.76%	 2010	 <5%	 IBBS	








63.2%	 2011	 75%	 IBBS	
Percentage	of	men	reporting	the	use	of	a	condom	the	
last	time	they	had	anal	sex	with	a	male	partner	


















1083	 Jun-2013	 1050	 NGO	reports	
Number	of	Female	Sex	Workers	(FSW)	reached	through	
a	basic	package	of	HIV/AIDS	prevention	services	
641	 Jun-2013	 800	 NGO	reports	
Number	of	people	who	receive	HIV	testing	and	
counseling	including	provision	of	test	results	

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































reciprocal obligations. For development assistance agencies these principles
should be reflected in corporate scorecards consistent with results-based
management principles (figure 3).
This is a demanding agenda considering that the record of monitoring and
evaluation has been dismal even at the project level. This is partly
explained by a lack of domestic evaluation capacity. But it is also due to
distorted organizational incentives and to the high priority given to inputs
versus results (i.e., outputs, outcomes, and impacts) by aid donors and
recipients alike. Meager resort to independent verification by qualified
academic institutions and voluntary agencies compounds the problem.
Furthermor , the fragmentation of aid among hundreds of proje ts
translates into high costs for expert data collection and interpretation.
Unless donors change their aid procedures to deliver aid on a
programmatic, common pool basis, it is doubtful that the situation will
improve rapidly.
At the country level, donor efforts have focused on generating household
surveys and improving national statistics. Public expenditure program
evaluation through logical frameworks, tracking surveys, and participatory
Implications for Performance Measurement 11





I Contribution to Millennium
Development Goals
II Country Program Results
III Partnership Processes 
(CDF, PRSP, UNDAF)
IV Financial & Knowledge 
Products

























































































IMPROVED HEALTH (LEVEL AND EQUITY)
RESPONSIVENESS
SOCIAL AND FINANCIAL RISK PROTECTION
IMPROVED EFFICIENCY





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































the other, however, guidance on combining qualitative and
quantitative data of equal weight, for example, in con-
current mixed methods studies, is rather less clear (Foss and
Ellefsen, 2002). This is made all the more challenging by a
common flaw which is to insufficiently and inexplicitly
identify the relationships between the epistemological and
methodological concepts in a particular study and the
theoretical propositions about the nature of the phenomena
under investigation (Kelle, 2001).
One approach to combining different data of equal
weight and which facilitate clear identification of the links
between the different levels of theory, epistemology, and
methodology could be to frame triangulation as a
‘methodological metaphor’, as argued by Erzberger and
Kelle (2003). This can help to; describe the logical relations
between the qualitative and quantitative findings and the
theoretical concepts in a study; demonstrate the way in
which both qualitative and quantitative data can be
combined to facilitate an improved understanding of
particular phenomena; and, can also be used to help
generate new theory (Erzberger and Kelle, 2003) (see
Fig. 1). The points of the triangle represent theoretical
propositions and empirical findings from qualitative and
quantitative data while the sides of the triangle represent
the logical relationships between these propositions and
findings. The nature and use of the triangle depends upon
the outcome from the analysis, whether that be convergent,
where qualitative and quantitative findings lead to the
same conclusion; complementary, where qualitative and
quantitative results can be used to supplement each other
or; divergent, where the combination of qualitative and
quantitative results provides different (and at times
contradictory) findings. Each of these outcomes requires
a different way of using the triangulation metaphor to link
theoretical propositions to empirical findings (Erzberger
and Kelle, 2003).
1.1. Purpose of this paper
In the following paper, we identify the analytical
approaches used in mixed methods healthcare research
and exemplify the use of triangulation (Erzberger and
Kelle, 2003) as a methodological metaphor for drawing
inferences from qualitative and quantitative findings.
Papers reporting on mixed methods studies within
healthcare research were reviewed to (i) determine the
type of analysis approach used, i.e. parallel, concurrent, or
sequential data analysis and, (ii) identify studies which
could be used to illustrate the use of the methodological
metaphor of triangulation suggested by Erzberger and
Kelle (2003). Four papers were selected to illustrate the
application of the triangulation metaphor on complemen-
tary, convergent and divergent outcomes and to develop
theory.
2. Methods
This literature review has used systematic principles
(Cochrane, 2009, Khan, 2001) to search for mixed methods
studies within healthcare research. The first search was
conducted in September 2009 in the data bases CINAHL,
Medline and PsycINFO on papers published in English
language between 1999 and 2009. To identify mixed
methods studies, the search terms (used as keywords and
where possible as MeSH terms) were: ‘‘mixed methods’’,
‘‘mixed research methods’’, ‘‘mixed research’’, ‘‘triangula-
tion’’, ‘‘complementary methods’’, ‘‘concurrent mixed
analysis’’ and ‘‘multi-strategy research.’’ These terms were
searched individually and then combined (with OR). This
resulted in 1896 hits in CINAHL, 1177 in Medline and 1943
in PsycINFO.
To focus on studies within, or relevant to, a healthcare
context the following search terms were used (as key-
words or as MeSH terms and combined with OR): ‘‘health
care research’’; ‘‘health services research’’; and ‘‘health’’.
These limits applied to the initial search (terms combined
with AND) resulted in 205 hits in Medline and 100 hits in
PsycINFO. Since this combination in CINAHL only limited
the search results to 1017; a similar search was conducted
but without using the search term triangulation to capture
mixed methods papers; resulting in 237 hits. In CINAHL










Fig. 1. Illustrating the triangulation triangle (Erzberger and Kelle, 2003)

































































































































































































































































































































































































































2007	 8.1	 8.5	 7.1	 5.3	 6.5	 8.5	 9.5	 7.9	 6.9	 9.0	 8.8	 8.8	 94.9	
2008	 8.1	 8.6	 7.1	 5.3	 6.5	 8.2	 9.0	 8.0	 6.9	 8.8	 8.5	 8.8	 93.8	
2009	 8.4	 9.0	 7.3	 5.7	 6.8	 8.4	 9.4	 8.4	 7.0	 9.0	 8.8	 9.0	 97.2	



























































































































1.	Legitimate	Politics	 	 	 3	 	 	
2.	Security	 	 	 3.5	 	
3.	Justice	 	 2	 	 	 	
4.	Economic	foundation	 	 2.5	 	 	



























































































































































































































































































Evaluating health systems reform and strengthening: 































































based CHeSS platform will bring together the key documents, standards, country activities and
results.Thiswillserveasanentrypointforcountryhealthsystemssurveillancepageswhereresults










Countries receiving financial support throughHSS joint programmingwill report annually on the
amountof fundsreceived forHSSprogramming fromdifferentsourcesandthebreakdownofhow
thosefundsareused.Thereportingburdenshouldnotbeonerous,butitmustbesufficienttotrack
theamountofresourcesbeing invested inHSSprogramming inacountrybydifferentpartnersand
the amount spent by category. Donors investing in HSS joint programming will use harmonised
categoriesforclassifyingexpenditures,sothatcountriesonlyhavetoreportonesetofexpenditure
figures to donors rather than reporting separately for different donors. Balancewill have to be
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Facility	 Location	 Public	 Private	 Total	
Health	Posts	 Suco/Parish	 192	 0	 192	
Community	Health	Centers	
(CHCs)	




Secondary	Referral	Hospital	 In	selected	five	districts	 5	 0	 5	
Tertiary	Referral	Hospital	 In	capital	Dili	 1	 0	 1	






























































































































Category/Sub-category	 2001	 2008	 2011	
General	Medical	Practitioners	 3	 37	 75	
Medical	Specialists	 0	 1	 9	
Dentists	 1	 2	 7	
Dental	Nurses	and	Technicians	 9	 29	 39	
Pharmacists	 0	 4	 15	
Pharmacy	Technicians	and	Assistants	 3	 44	 116	
Nursing	and	Midwifery	Practitioners	 474	 1104	 1283	
Non-medical	Public	Health	Practitioners	 25	 85	 122	
Medical	Technologists	 34	 107	 180	
Optometrists	 1	 3	 13	
Physiotherapists	 0	 1	 1	
Health	Management	and	Support	Staff	 92	 541	 621	









































30,799	 32,893	 35,692	 38,198	 44,480	 62,058	
Donor	funding	in	Health	Sector	(in	
thousand	US	dollars)	
27,700	 20,001	 30,314	 35,782	 31,109	 36,028	
Total	Health	Expenditure	(Govt	
and	donors	in	thousand	US	dollars)	




47.35%	 37.81%	 45.93%	 48.37%	 41.16%	 36.73%	
Estimated	per	capita	health	
expenditure	(Govt	&	donors)	
$54	 	 	 	 $64	 	
Govt	per	capita	expenditure	on	
health	
$29	 	 	 	 $37	 	
Appropriation	of	govt	health	
budget	of	total	govt	budget	
6.36%	 5.45%	 4.69%	 3.48%	 3.71%	 3.77%	
Percentage	of	ODA	in	total	
combined	budget	of	the	country		































30,799	 32,893	 35,692	 38,198	 44,480	 62,058	
Salaries	&	wages	 6,177	 8,189	 10,369	 11,063	 16,133	 22,468	
Goods	and	services	 18,123	 16,240	 12,695	 14,982	 17,261	 21,088	
Transfer	 250	 0	 1030	 10345	 9064	 11213	
Minor	capital	 3,481	 985	 1,277	 1,758	 1,950	 7,289	






















































































































2.	Malaria	 104	 2.	TB	(all	forms)	 0.15	
3.	Diarrhoea	 60	 3.	Diarrhoeal	disease	 0.05	
4.	Pneumonia	 46	 4.	Malaria	 0.05	

























































































































































































































































































































































































































13	 3.73	 0.439	 15	 4.17	 0.523	 11	 2.89	 0.944	


































13	 2.69	 0.630	 15	 3.47	 0.743	 10	 3	 0.667	













13	 2.92	 0.732	 12	 3.58	 0.821	 11	 3.18	 0.982	
14	 Efficiency:	Productivity	measure	 13	 2.92	 0.641	 15	 3.83	 0.523	 11	 3.59	 1.158	
15	 Efficiency:	Business	lead	time—
Regular	activities	
13	 2.60	 0.733	 15	 3.3	 0.797	 11	 3.77	 0.607	
16	 Efficiency:	Business	lead	time—
Exceptional	activities	





















13	 3.5	 0.764	 15	 4.33	 0.523	 11	 4.27	 0.786	
20	 Effectiveness:	Theory	of	Change	 13	 3.15	 0.875	 15	 4	 0.655	 11	 3.86	 0.636	


























































6	 5	 7	 6	 6	 1	
6	 Harmonization:	Take	part	in	joint	
mission	and	joint	country	analytic	work	








10	 8	 9	 9	 9	 1	
9	 Economy:	Unit	costs	 10	 10	 8	 9.33	 10	 1.155	
	 172	







5	 5	 7.5	 5.83	 6	 1.443	












10	 10	 9	 9.67	 10	 0.577	
14	 Efficiency:	Productivity	measure	 6	 10	 10	 8.67	 9	 2.309	
15	 Efficiency:	Business	lead	time—Regular	
activities	
8	 8	 8.5	 8.17	 8	 0.289	
16	 Efficiency:	Business	lead	time—
Exceptional	activities	




















8	 9	 8	 8.33	 8	 0.577	
20	 Effectiveness:	Theory	of	Change	 9	 5	 10	 8	 8	 2.65	










































1	 Ownership	 10	 50	 28.85	 38.83	 30.00	
2	 Alignment	 10	 50	 33.85	 38.00	 33.18	
3	 Alignment	 8	 40	 27.69	 28.53	 25.45	
4	 Alignment	 3	 15	 7.50	 9.20	 5.59	
5	 Alignment	 6	 30	 15.00	 18.40	 9.82	
6	 Harmonization	 9	 45	 31.15	 31.20	 36.20	
7	 Managing	for	
results	
10	 50	 26.15	 39.00	 36.36	
8	 Mutual	
accountability	
9	 45	 33.58	 37.50	 25.98	
Total	 Paris	principles	 		 325	 203.77	 240.67	 202.59	
	 Converted	score	
out	of	100	






































































































































































Ownership	 28.85	 38.83	 30.00	 50	 20	 11.54	 15.53	 12.00	
Alignment	 84.04	 94.13	 74.05	 135	 20	 12.45	 13.95	 10.97	
Harmonization	 31.15	 31.20	 36.20	 45	 20	 13.85	 13.87	 16.09	
Results	 26.15	 39.00	 36.36	 50	 20	 10.46	 15.60	 14.55	
Accountability	 33.58	 37.50	 25.98	 45	 20	 14.92	 16.67	 11.55	
	 178	







































































6	 30	 16.15	 20.80	 18.00	
11	 Economy:	
Procurement		
10	 50	 31.92	 33.33	 36.25	
Total	 Economy	 		 130	 73.46	 87.70	 87.75	
		 Converted	score	out	of	
100	



















































































12	 Project	Outputs	 10	 50	 27.69	 36.67	 35.45	
13	 Health	system	
Outputs	
10	 50	 29.23	 35.83	 31.82	
14	 Productivity	
measure	
9	 45	 26.31	 34.50	 32.32	
15	 Business	lead	time	
for	regular	activities	




8	 40	 20.62	 22.93	 22.00	
Total	 Efficiency	 		 225	 124.62	 156.33	 151.77	
		 Converted	score	out	
of	100	

















































































































17	 Project	outcome	 9	 45	 23.19	 33.38	 33.55	
18	 Health	systems	
outcome	




8	 40	 28.00	 34.67	 34.18	
20	 Effectiveness	of	
theory	of	change	
8	 40	 25.23	 32.00	 30.91	
		 Effectiveness	 		 165	 101.04	 128.84	 126.27	
		 Converted	score	
out	of	100	




































































































































21	 Leverage	&	replication	 8	 40	 26.15	 20.80	 26.18	
22	 Expected	lasting	effect	 10	 50	 25.19	 25.33	 33.64	
	Total	 Sustainability	 		 90	 51.35	 46.13	 59.82	
		 Converted	score	out	of	
100	








































































	 HSSP-SP	 NAP	 IPL	
Compliance	with	Paris	principles	 62.70	 74.05	 62.34	
Economy	 56.51	 67.47	 67.50	
Efficiency	 55.38	 69.48	 67.45	
Effectiveness	 61.24	 78.09	 76.53	
Sustainability	 57.05	 51.26	 66.46	
Total	 292.88	 340.34	 340.28	









































































































































































































































































































































































































































































































































































































































































































































































































































































	 	 	 	 	 	
	 Communicable,	neo-natal,	peri-natal	and	
nutritional	diseases	
29,738	 28,251	 27,121	 26,307	 25,781	
13.3%	
	 Non-Communicable	diseases	 20,592	 19,563	 18,780	 18,217	 17,852	 13.3%	
	 Injuries	 3,518	 3,342	 3,208	 3,112	 3,050	 13.3%	
	 Total	 53,848	 51,156	 49,109	 47,636	 46,683	 13.3%	
b.	With	intervention	(actual	scenario)	 	 	 	 	 	 	
	 Communicable,	neo-natal,	peri-natal	and	
nutritional	diseases	
29,738	 27,514	 25,291	 24,774	 24,257	
18.4%	
	 Non-Communicable	diseases	 20,592	 20,349	 20,105	 17,819	 15,533	 24.6%	
	 Injuries	 3,518	 3,437	 3,356	 3,825	 4,294	 -22.1%	
	 Total	 53,848	 51,300	 48,752	 46,418	 44,084	 18.1%	
c.	With	pessimistic	targets	(pessimistic	target	
scenario)	
	 	 	 	 	 	
	 Communicable,	neo-natal,	peri-natal	and	
nutritional	diseases	
29,738	 27,782	 25,826	 23,870	 21,914	
26.3%	
	 Non-Communicable	diseases	 20,592	 19,684	 18,776	 17,868	 16,960	 17.6%	
	 Injuries	 3,518	 3,325	 3,131	 2,938	 2,745	 22.0%	
	 Total	 53,848	 50,791	 47,733	 44,676	 41,619	 22.7%	
d.	With	optimistic	targets	(optimistic	target	
scenario)	
	 	 	 	 	 	
	 Communicable,	neo-natal,	peri-natal	and	
nutritional	diseases	
29,738	 27,137	 24,537	 21,936	 19,336	
35.0%	
	 Non-Communicable	diseases	 20,592	 19,550	 18,508	 17,466	 16,424	 20.2%	
	 Injuries	 3,518	 3,287	 3,055	 2,824	 2,592	 26.3%	







































	 2008	 2009	 2010	 2011	 2012	 Total	
Population	 1,050,244	 1,064,191	 1,079,450	 1,096,293	 1,114,106	 	
Total	DALYs	without	
intervention	
565,535	 544,393	 530,111	 522,231	 520,102	 	
Total	DALYs	with	current	results	 565,535	 545,930	 526,255	 508,879	 491,144	 	
Total	DALYs	with	pessimistic	
targets	
565,535	 540,509	 515,257	 489,779	 463,675	 	
Total	DALYs	with	optimistic	
targets	
565,535	 531,819	 497,628	 462,924	 427,286	 	
DALY	averted	by	HSSP-SP:	
Current	results	
0	 -1,538	 3,856	 13,352	 28,958	 44,628	
DALY	averted	by	HSSP-SP:	
Pessimistic	targets	
0	 3,884	 14,854	 32,452	 56,427	 107,616	
DALY	averted	by	HSSP-SP:	
Optimistic	targets	
0	 12,573	 32,482	 59,307	 92,815	 197,178	
Crude	Technical	Efficiency	
against	pessimistic	targets	
n/a	 -39.59%	 25.96%	 41.14%	 51.32%	 41.47%	
Crude	Technical	Efficiency	
against	optimistic	targets	












































































































































































































0	 -18.6	 0	 0	 0	 -10.6	 0	 0	 -0.3	
Mass	media	 0	 -11.5	 -17	 0	 0	 -4.2	 0	 0	 0	
VCT	 -34	 -16	 -18.3	 0	 -60.5	 -2.4	 0	 0	 0	
Condoms	 -76	 -18.9	 -24.2	 0	 0	 -6.5	 0	 0	 0	
Youth:	in-
school	
0	 -13.4	 0	 0	 0	 -22.1	 0	 0	 1	
Youth:	out-of-
school	
0	 -33.3	 0	 0	 0	 -77.4	 0	 0	 -0.8	
Workplace	
programmes	
0	 -23.2	 -22.6	 0	 0	 -9.7	 0	 0	 0	
Sex	workers	 -36.5	 0	 0	 0	 -38.1	 0	 0	 0	 0	
MSM:	outreach	 0	 0	 0	 -25.3	 0	 0	 0	 0	 0	
MSM:	
lubricants	













































































































































	 2005	 2006	 2007	
HIV	prevalence	total	population	 0.00013672	 0.000241302	 0.000394384	
HIV	prevalence	FSW	 0.0317	 0.027540535	 0.028224687	







HIV	prevalence	MSM	 0.0105	 0.016809346	 0.026875313	












	 2007	 2008	 2009	 2010	 2011	 2012	 2013	
Total	adult	population	
(15-49	male	and	female)	
431,132	 440,530	 452,880	 467,927	 483,815	 498,192	 510,364	
Male-	Not	sexually	active	 24,285	 25,904	 27,997	 30,074	 31,416	 31,599	 30,847	
Male-	Low	risk	
heterosexual	
118,048	 119,556	 121,687	 124,714	 128,578	 132,892	 137,365	
Male-	Medium	risk	
heterosexual	
46,158	 47,034	 48,262	 49,921	 51,882	 53,847	 55,606	
Male-	High	risk	
heterosexual	
21,862	 22,280	 22,865	 23,657	 24,595	 25,536	 26,378	
Male-	Men	who	have	sex	
with	men	(MSM)	
5,117	 5,234	 5,397	 5,619	 5,888	 6,176	 6,448	
Total	Male	adult	
population	(15-49)	
215,471	 220,007	 226,209	 233,985	 242,359	 250,050	 256,645	
Female-	Not	sexually	
active	
23,739	 25,263	 27,210	 29,081	 30,230	 30,308	 29,534	
Female-	Low	risk	
heterosexual	
127,388	 129,317	 131,731	 134,873	 138,684	 142,813	 147,012	
Female-	Medium	risk	
heterosexual	
63,498	 64,884	 66,643	 68,864	 71,378	 73,816	 75,933	
Female-	High	risk	
heterosexual	
1,037	 1,059	 1,088	 1,124	 1,165	 1,205	 1,240	
Total	Female	adult	
population	






















































































Intervention	 10%	 10%	 9%	 7%	 7%	 6%	 5%	
Targets	 8%	 5%	 4%	 3%	 3%	 3%	 2%	
No-intervention	 10%	 10%	 10%	 10%	 10%	 10%	 10%	
Medium	risk	
hetero-sexual	
Intervention	 16%	 16%	 15%	 10%	 10%	 9%	 8%	
Targets	 12%	 12%	 8%	 5%	 5%	 4%	 4%	
No-intervention	 16%	 16%	 16%	 16%	 16%	 16%	 16%	
High	risk	
hetero-sexual	
Intervention	 16%	 16%	 15%	 10%	 10%	 9%	 8%	
Targets	 12%	 10%	 8%	 5%	 5%	 4%	 4%	
No-intervention	 16%	 16%	 16%	 16%	 16%	 16%	 16%	
MSM	 Intervention	 18%	 18%	 16%	 12%	 10%	 9%	 8%	
Targets	 14%	 12%	 10%	 9%	 6%	 4%	 4%	









Intervention	 10%	 10%	 9%	 7%	 7%	 6%	 5%	
Targets	 8%	 7%	 6%	 3%	 3%	 3%	 2%	
No-intervention	 10%	 10%	 10%	 10%	 10%	 10%	 10%	
Medium	risk	
hetero-sexual	
Intervention	 16%	 16%	 15%	 10%	 10%	 9%	 8%	
Targets	 12%	 8%	 7%	 5%	 5%	 4%	 4%	
No-intervention	 16%	 16%	 16%	 16%	 16%	 16%	 16%	
High	risk	
hetero-sexual	
Intervention	 16%	 16%	 15%	 10%	 10%	 9%	 8%	
Targets	 12%	 8%	 7%	 5%	 5%	 4%	 4%	

















	 	 2007	 2008	 2009	 2010	 2011	 2012	 2013	
Male	Population	 	 	 	 	 	 	 	 	
Low	risk	hetero-
sexual	
Actual	 1	 1	 1	 1	 1	 1	 1	
Optimum	 1	 1	 1	 1	 1	 1	 1	
Counterfactual	 1	 1	 1	 1	 1	 1	 1	
Medium	risk	
hetero-sexual	
Actual	 2.4	 2.39	 2.38	 2.37	 2.36	 2.35	 2.34	
Optimum	 2.4	 2.37	 2.34	 2.31	 2.28	 2.25	 2.22	
Counterfactual	 2.4	 2.4	 2.4	 2.4	 2.4	 2.4	 2.4	
High	risk	hetero-
sexual	
Actual	 3.8	 3.58	 3.37	 3.16	 2.96	 2.76	 2.57	
Optimum	 3.8	 3.50	 3.21	 2.93	 2.66	 2.41	 2.16	
Counterfactual	 3.8	 3.8	 3.8	 3.8	 3.8	 3.8	 3.8	
MSM	 Actual	 8	 8	 8	 8	 8	 8	 8	
Optimum	 8	 8	 8	 8	 8	 8	 8	
Counterfactual	 8	 8	 8	 8	 8	 8	 8	
Female	
Population	
	 	 	 	 	 	 	 	
Low	risk	hetero-
sexual	
Actual	 1	 1	 1	 1	 1	 1	 1	
Optimum	 1	 1	 1	 1	 1	 1	 1	
Counterfactual	 1	 1	 1	 1	 1	 1	 1	
Medium	risk	
hetero-sexual	
Actual	 2.2	 2.19	 2.18	 2.17	 2.16	 2.16	 2.15	
Optimum	 2.2	 2.17	 2.14	 2.12	 2.09	 2.06	 2.03	
Counterfactual	 2.2	 2.2	 2.2	 2.2	 2.2	 2.2	 2.2	
High	risk	hetero-
sexual	
Actual	 160	 150.8	 141.9	 133.1	 124.6	 116.3	 108.2	
Optimum	 160	 147.4	 135.2	 123.5	 112.2	 101.4	 91.0	

















	 	 2007	 2008	 2009	 2010	 2011	 2012	 2013	
Number	of	sex	acts	per	partner	 	 	 	 	 	 	 	
Low	risk	hetero-
sexual	
Actual	 100	 100	 100	 100	 100	 100	 100	
Optimum	 100	 100	 100	 100	 100	 100	 100	
Counterfactual	 100	 100	 100	 100	 100	 100	 100	
Medium	risk	
hetero-sexual	
Actual	 50	 50	 50	 50	 50	 50	 50	
Optimum	 50	 50	 50	 50	 50	 50	 50	
Counterfactual	 50	 50	 50	 50	 50	 50	 50	
High	risk	hetero-
sexual	
Actual	 4.85	 5.19	 5.07	 4.81	 4.73	 4.73	 4.73	
Optimum	 4.85	 5.19	 5.07	 4.81	 4.73	 4.73	 4.73	
Counterfactual	 3.8	 3.8	 3.8	 3.8	 3.8	 3.8	 3.8	
MSM	 Actual	 16	 16	 16	 15	 15	 15	 15	
Optimum	 16	 16	 16	 15	 15	 15	 15	
Counterfactual	 16	 16	 16	 15	 15	 15	 15	
Condom	use	 	 	 	 	 	 	 	 	
Low	risk	hetero-
sexual	
Actual	 0%	 1.23%	 2.45%	 3.65%	 4.85%	 6.04%	 7.22%	
Optimum	 0%	 3.01%	 5.95%	 8.84%	 11.67%	 14.43%	 17.15%	
Counterfactual	 0%	 0%	 0%	 0%	 0%	 0%	 0%	
Medium	risk	
hetero-sexual	
Actual	 15%	 16.05%	 17.09%	 18.12%	 19.14%	 20.15%	 21.15%	
Optimum	 15%	 17.88%	 20.60%	 23.30%	 25.93%	 28.49%	 30.98%	
Counterfactual	 15%	 15%	 15%	 15%	 15%	 15%	 15%	
High	risk	hetero-
sexual	
Actual	 12%	 17.17%	 22.19%	 27.04%	 31.75%	 36.30%	 40.71%	
Optimum	 12%	 20.48%	 28.46%	 35.95%	 42.96%	 49.51%	 55.60%	
Counterfactual	 12%	 12%	 12%	 12%	 12%	 12%	 12%	
MSM	 Actual	 14%	 15.40%	 16.80%	 18.20%	 19.59%	 20.99%	 22.39%	
Optimum	 14%	 16.49%	 18.97%	 21.46%	 23.95%	 26.43%	 28.92%	



























General	population:	 	 	 	
Community	mobilization:	Reached	by	intervention	per	year	 0%	 10%	 40%	
Mass	media:	Reached	by	campaigns	per	year	 0%	 15%	 50%	
Adult	population	receiving	VCT	each	year	 0%	 20%	 30%	
Condom	coverage	 0%	 10%	 30%	
Workforce	receiving	peer	education	 0%	 60%	 80%	
Workforce	receiving	STI	treatment	 0%	 50%	 80%	
Most	at	risk	population:	 	 	 	
Female	sex	workers	reached	by	intervention	per	year	 0%	 75%	 100%	
Male	sex	workers	reached	by	intervention	per	year	 0%	 90%	 100%	
MSMs	reached	by	intervention	per	year	 0%	 45%	 80%	
MSMs	receiving	lubricants	 0%	 45%	 80%	
Medical	services:	 	 	 	
Males	with	STI	receiving	treatment	 10%	 50%	 80%	
Females	with	STI	receiving	treatment	 10%	 50%	 80%	
Units	of	blood	for	transfusion	tested	 100%	 100%	 100%	
Post-exposure	prophylaxis	need	that	is	met	 0%	 0%	 0%	
Unsafe	medical	injections	replaced	with	AD	syringes	 0%	 98%	 100%	













Actual	 0	 1	 1	 3	 1	 15	 7	
Optimum	 0	 1	 4	 4	 7	 40	 70	
Counterfactual	 0	 0	 0	 0	 0	 0	 0	
Adults	receiving	
ART	
Actual	 8	 22	 29	 36	 89	 79	 129	
Optimum	 8	 24	 25	 36	 200	 201	 298	


















		 2007	 2008	 2009	 2010	 2011	 2012	 2013	 Total	
Counterfactual	scenario:	 		 		 		 		 		 		 		 		
Deaths	averted	by	ART	 3	 2	 1	 1	 1	 2	 2	 12	
Infections	averted	by	PMTCT	 0	 0	 0	 0	 0	 0	 0	 0	
Life	years	gained	by	ART	and	
PMTCT	
6	 8	 10	 12	 14	 16	 19	 85	
Actual	scenario:	 		 		 		 		 		 		 		 	
Deaths	averted	by	ART	 3	 2	 6	 7	 8	 15	 16	 57	
Infections	averted	by	PMTCT	 0	 0	 0	 0	 0	 2	 1	 3	
Life	years	gained	by	ART	and	
PMTCT	




0	 1	 6	 12	 20	 36	 53	 128	
Optimum	scenario:	 		 		 		 		 		 		 		 	
Deaths	averted	by	ART	 3	 2	 7	 6	 10	 27	 32	 87	
Infections	averted	by	PMTCT	 0	 0	 0	 0	 1	 4	 5	 10	
Life	years	gained	by	ART	and	
PMTCT	




0	 1	 6	 12	 22	 51	 86	 178	
Treatment	services	efficiency	 n/a	 100%	 100%	 100%	 90.9%	 70.6%	 61.6%	 71.9%	

































Actual	scenario	 128	 0.947	 121.216	
Optimum	scenario	 178	 0.947	 168.566	







































		 2007	 2008	 2009	 2010	 2011	 2012	 2013	 Total		
New	infections	averted	by	
current	intervention	




24	 65	 127	 181	 260	 370	 456	 1483	
Efficiency	in	averting	new	
infections	
0.00%	 10.77%	 33.07%	 56.35%	 60.38%	 61.35%	 63.82%	 55.70%	
Deaths	averted	by	current	
intervention	




0	 1	 5	 6	 12	 31	 40	 95	
Efficiency	in	averting	
deaths	
























































B1	+	B2	+	B3	 27,838.84	 49,981.85	 55.70%	
C.	AIDS	with	ART	for	
16.5	years:	




























C1	+	C2	+	C3	 3,403.33	 6,110.33	 55.70%	
D.	AIDS	with	life	long	
ART:	

























D1	+	D2	+	D3	 546.07	 980.41	 55.70%	
E.	AIDS	with	ART	for	11	
years:	




























E1	+	E2	+	E3	 3,783.16	 6,792.29	 55.70%	
Total	DALYs	averted	by	
Prevention	Programme		


















Total	DALYs-	STD	excluding	HIV	 3,605.6	 2,176.1	 1,429.5	
Estimated	DALYs	without	intervention	 3,605.6	 2,890.8	 714.7	
Estimated	DALYs	if	full	targets	achieved	 3,605.6	 1,461.4	 2,144.2	
DALYs	averted	by	intervention	 	 	 714.7	
DALYs	averted	if	full	targets	achieved	 	 	 1,429.5	



























	 Results	 Targets	 Efficiency	
DALYs	saved	by	ART	and	PMTCT	programme	components	 121.22	 168.57	 71.91%	
DALYs	saved	by	Prevention	Programme	components	 38,414.24	 69,058.53	 55.63%	
DALYs	saved	by	STI	Programme	components	 714.75	 1,429.50	 50.00%	























Total	Cost	of	Global	Fund	funded	NAP	activities	 $11,842,703	 $14,446,916	 81.97%	























































































































































































































































































	 2010	 2011	 2012	 2013	
Total	number	of	children	eligible	for	vaccination	 42,188	 42,188	 38,915	 39,497	
Number	of	children	eligible	for	vaccination	in	
IPL-focus	districts	
28,574	 28,574	 26,357	 26,751	
Number	of	children	eligible	for	vaccination	in	
IPL-non-focus	districts	
13,614	 13,614	 12,558	 12,746	
Number	of	children	vaccinated	for	DPT3	in	IPL-
focus	districts	
19,408	 18,479	 22,101	 17,236	
Coverage	of	DPT3	vaccination	in	IPL-focus	
districts	
67.92%	 64.67%	 83.85%	 64.43%	
Number	of	children	vaccinated	for	DPT3	in	IPL-
non-focus	districts	
11,116	 9,800	 10,043	 6,741	
Coverage	of	DPT3	vaccination	in	IPL-non-focus	
districts	
81.65%	 71.98%	 79.97%	 52.89%	
Number	of	children	vaccinated	for	measles	in	
IPL-focus	districts	
16,890	 18,083	 19,362	 18,454	
Coverage	of	measles	vaccination	in	IPL-focus	
districts	
59.11%	 63.29%	 73.46%	 68.98%	
Number	of	children	vaccinated	for	measles	in	
IPL-non-focus	districts	
11,032	 9,207	 9,039	 5,776	
Coverage	of	measles	vaccination	in	IPL-non-
focus	districts	
























Formula	component	 Diphtheria	 Pertussis	 Tetanus	 Measles	
Total	number	of	children	eligible	for	vaccination	 81682	 81682	 81682	 81682	
Proportion	of	vaccination	coverage	 70.78%	 70.78%	 70.78%	 68.44%	




0.08%	 80%	 65%	 100%	
Vaccine	effectiveness	(VE)	 80%	 80%	 90%	 90%	
Number	of	prevented	cases,	I	=	V*S*VE	 35	 37,002	 33,822	 50,309	
Case	fatality	ratio	(CFR)	 10%	 2%	 35%	 3%	








Formula	component	 Diphtheria	 Pertussis	 Tetanus	 Measles	
Total	number	of	children	eligible	for	vaccination	 81682	 81682	 81682	 81682	
Proportion	of	vaccination	coverage	 0.815	 0.815	 0.815	 0.815	





0.08%	 80%	 65%	 100%	
Vaccine	effectiveness	(VE)	 80%	 80%	 90%	 90%	
Number	of	prevented	cases,	I	=	V*S*VE	 40	 42,605	 38,944	 59,914	
Case	fatality	ratio	(CFR)	 10%	 2%	 35%	 3%	

















Calculation	parameters	 Diphtheria	 Pertussis	 Tetanus	 Measles	
Average	age	of	disease	onset	(years)	 3	 5.5	 15	 2	
Average	life	expectancy	at	disease	onset	 89.41	 84.52	 74.54	 89.41	
Average	age	at	death	due	to	disease	 3	 5.5	 15	 2	
Life	expectancy	at	average	age	at	death	(LE)	 89.41	 84.52	 74.54	 89.41	
Year	of	Life	Lost	(YLL)	averted	=	N*LE	 310.16	 62,548.75	 882,393.89	 134,944.28	
Average	duration	of	disease	episode	(in	years)	(L0)	 0.1	 0.1	 0.16	 0.038	
Disability	weight	(DW)	for	the	disease	episode	(DW0)	 0.23	 0.178	 0.64	 0.152	
Averted	Years	Lived	in	Disability	(YLD)	during	disease	
episode,	YLD0	=	I*L0*DW0	





2%	 0.50%	 15%	 	
Average	duration	of	disease	sequelae	1	(in	years)	(L1)	 89.41	 84.52	 74.54	 	
Disability	weight	(DW)	for	the	disease	sequelae	1	
(DW1)	
0.078	 0.469	 0.388	 	
Averted	Years	Lived	in	Disability	(YLD)	during	disease	
sequelae	1,	YLD1	=	I*P1*L1*DW1	





15%	 	 15%	 	
Average	duration	of	disease	sequelae	2	(in	years)	(L2)	 89.41	 	 74.54	 	
Disability	weight	(DW)	for	the	disease	sequelae	2	
(DW2)	
0.323	 	 0.469	 	
Averted	Years	Lived	in	Disability	(YLD)	during	disease	
sequelae	2,	YLD2	=	I*P2*L2*DW2	
150.27	 	 177,361.17	 	
Total	Years	Lived	in	Disability	(YLD)	averted,	YLD	=	
YLD0+YLD1+YLD2	
155.91	 7,992.48	 327,554.09	 290.59	







Calculation	parameters	 Diphtheria	 Pertussis	 Tetanus	 Measles	
Average	age	of	disease	onset	(years)	 3	 5.5	 15	 2	
Average	life	expectancy	at	disease	onset	 89.41	 84.52	 74.54	 89.41	
Average	age	at	death	due	to	disease	 3	 5.5	 15	 2	
Life	expectancy	at	average	age	at	death	(LE)	 89.41	 84.52	 74.54	 89.41	
Year	of	Life	Lost	(YLL)	averted	=	N*LE	 357.1	 72,020.1	 1,016,008.3	 160,706.6	
Average	duration	of	disease	episode	(in	years)	
(L0)	
0.1	 0.1	 0.16	 0.038	
Disability	weight	(DW)	for	the	disease	episode	
(DW0)	
0.23	 0.178	 0.64	 0.152	
Averted	Years	Lived	in	Disability	(YLD)	during	
disease	episode,	YLD0	=	I*L0*DW0	





2%	 0.50%	 15%	 	
Average	duration	of	disease	sequelae	1	(in	years)	
(L1)	
89.41	 84.52	 74.54	 	
Disability	weight	(DW)	for	the	disease	sequelae	1	
(DW1)	
0.078	 0.469	 0.388	 	
Averted	Years	Lived	in	Disability	(YLD)	during	
disease	sequelae	1,	YLD1	=	I*P1*L1*DW1	





15%	 	 15%	 	
Average	duration	of	disease	sequelae	2	(in	years)	
(L2)	
89.4	 	 74.5	 	
Disability	weight	(DW)	for	the	disease	sequelae	2	
(DW2)	
0.323	 	 0.469	 	
Averted	Years	Lived	in	Disability	(YLD)	during	
disease	sequelae	2,	YLD2	=	I*P2*L2*DW2	
173	 	 204,217.7	 	
Total	Years	Lived	in	Disability	(YLD)	averted,	YLD	
=	YLD0+YLD1+YLD2	
179.5	 9,202.7	 377,153.2	 346.1	
















































IPL	focus	areas	 67.92%	 70.78%	 2.86%	 59.11%	 68.43%	 9.32%	
Non-IPL	focus	areas	 81.65%	 68.31%	 -13.34%	 81.03%	 61.72%	 -19.31%	
%	of	change	
attributable	to	IPL	













	 Diphtheria	 Pertussis	 Tetanus	 Measles	 Total	
Total	DALYs	saved	by	
vaccination	
466.07	 70,541.24	 1,209,947.98	 135,234.87	 1,416,190	
Proportion	of	achievement	
attributable	to	IPL		
16.2%	 16.2%	 16.2%	 28.63%	 	
DALYs	saved	attributable	to	
IPL	
75.50	 11,427.68	 196,011.57	 38,717.74	 246,232.50	
Cost	of	IPL	 $659,812.50	 $659,812.50	 $659,812.50	 $659,812.50	 $2,639,250	







































IPL	focus	areas	 67.92%	 81.50%	 13.58%	 59.11%	 81.50%	 22.39%	
Non-IPL	focus	areas	 81.65%	 68.31%	 -13.34%	 81.03%	 61.72%	 -19.31%	
%	of	change	
attributable	to	IPL	
























26.92%	 26.92%	 26.92%	 41.7%	 	
Expected	DALYs	averted	
attributable	to	IPL	
144.46	 21,865.17	 375,039.09	 67,158.98	 464,207.70	




$4,567.30	 $30.18	 $1.76	 $9.82	 $5.69	
Technical	efficiency	of	IPL	
(actual	results	against	












































































Epidemiology	 Value	used	 Lower	range		 Upper	range		
Transmission	of	HIV	per	act		(female	to	male)	 0.0011	 0.00099	 0.00121	
Transmission	multiplier	for	male	to	female	 1	 0.9	 1.1	
Transmission	multiplier	for	STI	 4	 3.6	 4.4	
Transmission	multiplier	for	MSM	contacts	 2.6	 2.34	 2.86	
Relative	infectiousness	during	Primary	Infection	 8	 7.2	 8.8	































Diphtheria:	 	 	 	




Case	fatality	ratio	 10%	 5%	 20%	
Pertussis:	 	 	 	




Case	fatality	ratio	 2%	 0.50%	 10%	
Tetanus:	 	 	 	




Case	fatality	ratio	 35%	 30%	 40%	
Measles:	 	 	 	












	 Value	used	 Lower	range	 Upper	range	
HSSP-SP:	 	 	 	
Cost	per	DALY	saved	with	intervention	results	 $363.90	 $932.74	 $225.16	
Cost	per	DALY	saved	with	pessimistic	targets	 $195.14	 $202.17	 $188.72	
Technical	efficiency	against	pessimistic	targets	 53.62%	 21.68%	 83.82%	
Cost	per	DALY	saved	with	optimistic	targets	 $106.50	 $109.61	 $103.60	
Technical	efficiency	against	optimistic	targets	 29.27%	 11.75%	 46.01%	
NAP:	 	 	 	
Cost	per	DALY	saved	with	intervention	results	 $335.25	 $764.33	 $260.91	
Cost	per	DALY	saved	if	full	targets	achieved	 $227.19	 $612.72	 $163.14	
Technical	efficiency	 67.77%	 62.53%	 80.16%	
IPL:	 	 	 	
Cost	per	DALY	saved	with	intervention	results	 $10.72	 $18.35	 $5.67	
Cost	per	DALY	saved	if	full	targets	achieved	 $5.69	 $9.59	 $3.05	
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A	 1000	 20	 1	 1.00	 1.00	 1.00	 0.00	
B	 400	 40	 1	 0.59	 1.00	 0.59	 -0.41	
C	 200	 140	 1	 1.00	 1.00	 1.00	 0.00	
	 	 	 	 	 	 	 	



























































































































































Motorbike	 Projector	 	 USD	 	
HSSP-SP	 3	 11	 13	 60	 3	 	 $127,981	 87.2%	
NAP	 4	 51	 7	 15	 4	 	 $101,777	 100%	





































HSSP-SP	 41.5	 13	 3.19	 0.663	 63.85%	
NAP	 50	 15	 3.33	 0.816	 66.67%	





















































HSSP-SP	 152.6	 61.6	 	 $646,438	 100%	
NAP	 576	 55	 	 $774,444	 100%	






























61%	 73%	 90%	 41.38%	 41.38%	
3.	Percentage	of	births	attended	by	
skilled	health	personnel	
27%	 59%	 45%	 177.78%	 100%	
4.	Percentage	of	pregnant	women	
receiving	four	or	more	prenatal	visits	




36%	 57%	 80%	 47.73%	 47.73%	
6.	Contraceptive	Prevalence	Rate	 10	 26	 25	 106.67%	 100%	
7.	Number	of	formal	MOH-private	
sector/NGO	contracts	signed	
0	 6	 10	 60.00%	 60%	
8.	Availability	of	tracer	essential	
drugs	at	(i)	SAMES	





























1.	Percentage	of	sex	workers	who	are	HIV	infected	 2.76%	 2%	 <5%	 294.74%	 100%	








68.5%	 63%	 75%	 -84.62%	 0	
5.	Percentage	of	men	reporting	the	use	of	a	condom	the	
last	time	they	had	anal	sex	with	a	male	partner	






















840	 815	 800	 160%	 100%	
11.	Number	of	people	who	receive	HIV	testing	and	
counseling	including	provision	of	test	results	









30	 61	 80	 62%	 62%	
14.	Number	of	adults	and	children	with	advanced	HIV	
infection	currently	receiving	antiretroviral	treatment	








12	 13	 13	 100%	 100%	
17.	Number	of	civil	society/community	based	
organizations	received	capacity	development	support	



















































IPL	focus	districts	 67.92%	 70.78%	 2.86%	 59.11%	 68.43%	 9.32%	
Non-IPL	focus	
districts	




-13.73%	 2.47%	 16.20%	 -21.92%	 6.71%	 28.63%	
Targets	for	IPL	focus	
districts	
67.92%	 81.50%	 13.58%	 59.11%	 81.50%	 22.39%	
Non-IPL	focus	
districts	




































HSSP-SP	 38	 13	 2.92	 0.732	 58.46%	
NAP	 43	 12	 3.58	 0.821	 71.67%	















Project	 Total	budget	(USD)	 Total	expenditure	(USD)	 Use	of	allocated	resources	
HSSP-SP	 $21,000,000	 $16,240,000	 77.33%	
NAP	 $14,480,049	 $11,842,703	 81.97%	
























HSSP-SP	 54.62%	 58.46%	 	 77.33%	 88.89%	
NAP	 65.14%	 71.66%	 	 81.97%	 100%	



























HSSP-SP	 38	 13	 2.92	 0.641	 58.46%	
NAP	 57.5	 15	 3.83	 0.523	 76.67%	





























HSSP-SP	 40	 13	 3.08	 0.760	 61.54%	
NAP	 54	 15	 3.60	 0.660	 72.00%	













	 HSSP-SP	 NAP	 IPL	
Technical	assistance	 $4,883,423	 $4,109,267	 $887,052	
Infrastructure,	durable	goods	and	equipment	 $3,151,907	 $815,357	 $37,776	
Training	 $3,443,745	 $501,947	 $196,096	
Total	HSS	investments	 $11,479,075	 $5,426,571	 $1,120,924	
HSS	investment	as	%	of	total	expenditure	 70.68%	 45.82%	 42.47%	


















HSSP-SP	 44,628	 7,064,223	 	 $16,240,000	 100%	
NAP	 39,250.21	 3,907,131	 	 $11,842,703	 76.28%	







































45.5	 13	 3.50	 0.764	 70%	
20.	Theory	of	
change	
41	 13	 3.15	 0.875	 63.08%	
NAP	 19.	Relevance	&	
robustness	
65	 15	 4.33	 0.523	 86.67%	
20.	Theory	of	
change	
60	 15	 4.00	 0.655	 80%	
IPL	 19.	Relevance	&	
robustness	
47	 11	 4.27	 0.786	 85.45%	
20.	Theory	of	
change	































HSSP-SP	 87.2%	 100%	 88.89%	 100%	
NAP	 100%	 100%	 100%	 76.28%	

















































	Variable	 Total	score	 HSSP-SP	 NAP	 IPL	 Data	source	
Ownership	
50	
















33.58	 37.50	 25.98	 Stakeholder	interviews	
(Chapter	7)	
Paris	Principles	 325	 203.77	 240.67	 202.59	 Stakeholder	interviews	
(Chapter	7)	
Economy	 130	 73.46	 87.70	 87.75	 Stakeholder	interviews	
(Chapter	7)	
Efficiency	 225	 124.62	 156.33	 151.77	 Stakeholder	interviews	
(Chapter	7)	
Effectiveness	 165	 101.04	 128.84	 126.27	 Stakeholder	interviews	
(Chapter	7)	




100	 53.62%	 67.77%	 53.04%	 Cost	effectiveness	
analysis	(Chapter	8)	
Achievement	of	results	 100	 54.62%	 65.14%	 64.42%	 Project	results	
(Chapter	9)	












100	 70.68%	 45.82%	 42.47%	 Project	financial	reports	
(Chapter	9)	























Sample size 3 Critical value (2%) 31.82052




Alignment Spearman Correlation Coefficient 0.5 1.




Harmonization Spearman Correlation Coefficient 0.5 1. 1.




Managing Results Spearman Correlation Coefficient 1. 0.5 0.5 1.
R Standard Error 0.E+0 0.75 0.75
t #N/A 0.57735 0.57735
p-value #N/A 0.66667 0.66667
H0 (2%) accepted accepted
Accountability Spearman Correlation Coefficient 0.5 1. 1. 0.5 1.
R Standard Error 0.75 0.E+0 0.E+0 0.75
t 0.57735 #N/A #N/A 0.57735
p-value 0.66667 #N/A #N/A 0.66667
H0 (2%) accepted accepted
Paris Principles Spearman Correlation Coefficient 0.5 1. 1. 0.5 1. 1.
R Standard Error 0.75 0.E+0 0.E+0 0.75 0.E+0
t 0.57735 #N/A #N/A 0.57735 #N/A
p-value 0.66667 #N/A #N/A 0.66667 #N/A
H0 (2%) accepted accepted
Economy Spearman Correlation Coefficient 0.5 -0.5 -0.5 0.5 -0.5 -0.5
R Standard Error 0.75 0.75 0.75 0.75 0.75 0.75
t 0.57735 -0.57735 -0.57735 0.57735 -0.57735 -0.57735
p-value 0.66667 0.66667 0.66667 0.66667 0.66667 0.66667
H0 (2%) accepted accepted accepted accepted accepted accepted
Efficiency Spearman Correlation Coefficient 1. 0.5 0.5 1. 0.5 0.5
R Standard Error 0.E+0 0.75 0.75 0.E+0 0.75 0.75
t #N/A 0.57735 0.57735 #N/A 0.57735 0.57735
p-value #N/A 0.66667 0.66667 #N/A 0.66667 0.66667
H0 (2%) accepted accepted accepted accepted
Effectiveness Spearman Correlation Coefficient 1. 0.5 0.5 1. 0.5 0.5
R Standard Error 0.E+0 0.75 0.75 0.E+0 0.75 0.75
t #N/A 0.57735 0.57735 #N/A 0.57735 0.57735
p-value #N/A 0.66667 0.66667 #N/A 0.66667 0.66667
H0 (2%) accepted accepted accepted accepted
Sustainability Spearman Correlation Coefficient -0.5 -1. -1. -0.5 -1. -1.
R Standard Error 0.75 0.E+0 0.E+0 0.75 0.E+0 0.E+0
t -0.57735 #N/A #N/A -0.57735 #N/A #N/A
p-value 0.66667 #N/A #N/A 0.66667 #N/A #N/A
H0 (2%) accepted accepted
Spearman Correlation Coefficient 0.5 1. 1. 0.5 1. 1.
R Standard Error 0.75 0.E+0 0.E+0 0.75 0.E+0 0.E+0
t 0.57735 #N/A #N/A 0.57735 #N/A #N/A
p-value 0.66667 #N/A #N/A 0.66667 #N/A #N/A
H0 (2%) accepted accepted
Spearman Correlation Coefficient 1. 0.5 0.5 1. 0.5 0.5
R Standard Error 0.E+0 0.75 0.75 0.E+0 0.75 0.75
t #N/A 0.57735 0.57735 #N/A 0.57735 0.57735
p-value #N/A 0.66667 0.66667 #N/A 0.66667 0.66667
H0 (2%) accepted accepted accepted accepted
Spearman Correlation Coefficient 1. 0.5 0.5 1. 0.5 0.5
R Standard Error 0.E+0 0.75 0.75 0.E+0 0.75 0.75
t #N/A 0.57735 0.57735 #N/A 0.57735 0.57735
p-value #N/A 0.66667 0.66667 #N/A 0.66667 0.66667
H0 (2%) accepted accepted accepted accepted
Spearman Correlation Coefficient 1. 0.5 0.5 1. 0.5 0.5
R Standard Error 0.E+0 0.75 0.75 0.E+0 0.75 0.75
t #N/A 0.57735 0.57735 #N/A 0.57735 0.57735
p-value #N/A 0.66667 0.66667 #N/A 0.66667 0.66667
H0 (2%) accepted accepted accepted accepted
Cost per year Spearman Correlation Coefficient 0.5 -0.5 -0.5 0.5 -0.5 -0.5
R Standard Error 0.75 0.75 0.75 0.75 0.75 0.75
t 0.57735 -0.57735 -0.57735 0.57735 -0.57735 -0.57735
p-value 0.66667 0.66667 0.66667 0.66667 0.66667 0.66667
H0 (2%) accepted accepted accepted accepted accepted accepted
Spearman Correlation Coefficient -0.5 0.5 0.5 -0.5 0.5 0.5
R Standard Error 0.75 0.75 0.75 0.75 0.75 0.75
t -0.57735 0.57735 0.57735 -0.57735 0.57735 0.57735
p-value 0.66667 0.66667 0.66667 0.66667 0.66667 0.66667
H0 (2%) accepted accepted accepted accepted accepted accepted
Use of resoureces Spearman Correlation Coefficient -0.5 0.5 0.5 -0.5 0.5 0.5
R Standard Error 0.75 0.75 0.75 0.75 0.75 0.75
t -0.57735 0.57735 0.57735 -0.57735 0.57735 0.57735
p-value 0.66667 0.66667 0.66667 0.66667 0.66667 0.66667
H0 (2%) accepted accepted accepted accepted accepted accepted
Total expenditure Spearman Correlation Coefficient 0.5 -0.5 -0.5 0.5 -0.5 -0.5
R Standard Error 0.75 0.75 0.75 0.75 0.75 0.75
t 0.57735 -0.57735 -0.57735 0.57735 -0.57735 -0.57735
p-value 0.66667 0.66667 0.66667 0.66667 0.66667 0.66667
H0 (2%) accepted accepted accepted accepted accepted accepted
Spearman Correlation Coefficient -0.5 0.5 0.5 -0.5 0.5 0.5
R Standard Error 0.75 0.75 0.75 0.75 0.75 0.75
t -0.57735 0.57735 0.57735 -0.57735 0.57735 0.57735
p-value 0.66667 0.66667 0.66667 0.66667 0.66667 0.66667
H0 (2%) accepted accepted accepted accepted accepted accepted
Spearman Correlation Coefficient 0.5 1. 1. 0.5 1. 1.
R Standard Error 0.75 0.E+0 0.E+0 0.75 0.E+0 0.E+0
t 0.57735 #N/A #N/A 0.57735 #N/A #N/A
p-value 0.66667 #N/A #N/A 0.66667 #N/A #N/A
H0 (2%) accepted accepted
Cost effectiveness 
efficiency





















































Sample size 3 Critical value 
(2%)
31.82052




Alignment Pearson Correlation Coefficient 0.81025 1.




Harmonization Pearson Correlation Coefficient -0.39813 -0.86022 1.
R Standard Error 0.84149 0.26002
t -0.43401 -1.68698
p-value 0.73932 0.34065
H0 (2%) accepted accepted
Pearson Correlation Coefficient 0.73445 0.19732 0.33015 1.
R Standard Error 0.46059 0.96106 0.891
t 1.08219 0.20128 0.34976
p-value 0.47488 0.87355 0.7858
H0 (2%) accepted accepted accepted
Accountability Pearson Correlation Coefficient 0.68842 0.98289 -0.93943 0.01337 1.
R Standard Error 0.52607 0.03393 0.11747 0.99982
t 0.94915 5.33601 -2.74093 0.01337
p-value 0.5166 0.11794 0.22271 0.99149
H0 (2%) accepted accepted accepted accepted
Paris 
Principles
Pearson Correlation Coefficient 0.9912 0.88069 -0.51605 0.63816 0.77837 1.
R Standard Error 0.01752 0.22438 0.73369 0.59276 0.39414
t 7.48855 1.85923 -0.60247 0.82887 1.23983
p-value 0.08451 0.31415 0.6548 0.5594 0.43209
H0 (2%) accepted accepted accepted accepted accepted
Economy Pearson Correlation Coefficient 0.58596 -0.00016 0.51006 0.98031 -0.18436 0.47355
R Standard Error 0.65665 1. 0.73984 0.039 0.96601 0.77575
t 0.7231 -0.00016 0.59299 4.96404 -0.18757 0.53765
p-value 0.60144 0.9999 0.65925 0.12655 0.88196 0.68595
H0 (2%) accepted accepted accepted accepted accepted accepted
Efficiency Pearson Correlation Coefficient 0.69072 0.13584 0.38834 0.99806 -0.04897 0.58893
R Standard Error 0.5229 0.98155 0.84919 0.00388 0.9976 0.65316
t 0.9552 0.13711 0.42141 16.01406 -0.04903 0.72871
p-value 0.51459 0.91325 0.7461 0.0397 0.96881 0.5991
H0 (2%) accepted accepted accepted accepted accepted accepted
Effectiveness Pearson Correlation Coefficient 0.65399 0.08651 0.43359 0.99373 -0.09848 0.5481
R Standard Error 0.5723 0.99252 0.812 0.01249 0.9903 0.69959
t 0.86449 0.08684 0.48117 8.89053 -0.09896 0.6553
p-value 0.54619 0.94486 0.71449 0.07131 0.93721 0.6307
H0 (2%) accepted accepted accepted accepted accepted accepted
Sustainability Pearson Correlation Coefficient -0.72117 -0.99034 0.92261 -0.0595 -0.99893 -0.80652
R Standard Error 0.47992 0.01922 0.14879 0.99646 0.00213 0.34953
t -1.041 -7.14321 2.39184 -0.05961 -21.64467 -1.36417
p-value 0.48721 0.08855 0.2521 0.9621 0.02939 0.4027
H0 (2%) accepted accepted accepted accepted accepted accepted
Pearson Correlation Coefficient 0.99018 0.88423 -0.52248 0.63235 0.78307 0.99997
R Standard Error 0.01955 0.21814 0.72702 0.60014 0.3868 0.00006
t 7.08222 1.89322 -0.61277 0.81627 1.25909 132.9854
p-value 0.0893 0.30937 0.65002 0.56418 0.42731 0.00479
H0 (2%) accepted accepted accepted accepted accepted rejected
Pearson Correlation Coefficient 0.63684 0.06413 0.45371 0.99097 -0.12079 0.52919
R Standard Error 0.59443 0.99589 0.79415 0.01797 0.98541 0.71996
t 0.826 0.06426 0.50912 7.39241 -0.12168 0.62367
p-value 0.56048 0.95915 0.7002 0.0856 0.92291 0.64499
H0 (2%) accepted accepted accepted accepted accepted accepted
Pearson Correlation Coefficient 0.95704 0.6055 -0.11505 0.89968 0.44855 0.91024
R Standard Error 0.08407 0.63337 0.98676 0.19058 0.79881 0.17146
t 3.3007 0.76083 -0.11582 2.06084 0.50187 2.19825
p-value 0.18728 0.58594 0.92659 0.2876 0.70388 0.27179
H0 (2%) accepted accepted accepted accepted accepted accepted
Pearson Correlation Coefficient 0.78455 0.27227 0.25644 0.99703 0.09037 0.69558
R Standard Error 0.38447 0.92587 0.93424 0.00594 0.99183 0.51617
t 1.26529 0.28296 0.26531 12.94015 0.09074 0.96817
p-value 0.42578 0.82445 0.8349 0.0491 0.94239 0.5103
H0 (2%) accepted accepted accepted accepted accepted accepted
Cost per year Pearson Correlation Coefficient -0.32625 0.28968 -0.73724 -0.88115 0.46102 -0.19826
R Standard Error 0.89356 0.91609 0.45647 0.22358 0.78746 0.96069
t -0.34514 0.30265 -1.09119 -1.8635 0.51953 -0.20228
p-value 0.78843 0.8129 0.47226 0.31355 0.69497 0.87294
H0 (2%) accepted accepted accepted accepted accepted accepted
Pearson Correlation Coefficient -0.49705 0.10583 -0.59809 -0.95395 0.28718 -0.37782
R Standard Error 0.75294 0.9888 0.64229 0.08998 0.91753 0.85725
t -0.57282 0.10643 -0.74628 -3.18022 0.29981 -0.40807
p-value 0.66883 0.9325 0.59185 0.19395 0.81456 0.75334
H0 (2%) accepted accepted accepted accepted accepted accepted
Pearson Correlation Coefficient -0.2213 -0.75086 0.98269 0.49931 -0.85967 -0.34843
R Standard Error 0.95103 0.4362 0.03432 0.75069 0.26097 0.8786
t -0.22692 -1.13688 5.30435 0.57629 -1.68283 -0.37172
p-value 0.85794 0.45928 0.11863 0.66717 0.34134 0.77343
H0 (2%) accepted accepted accepted accepted accepted accepted
Pearson Correlation Coefficient 0.09561 0.66087 -0.95119 -0.60533 0.78781 0.22653
R Standard Error 0.99086 0.56325 0.09524 0.63357 0.37936 0.94869
t 0.09605 0.88058 -3.08225 -0.7605 1.27907 0.23257
p-value 0.93904 0.54037 0.19972 0.58608 0.42243 0.85453
H0 (2%) accepted accepted accepted accepted accepted accepted
Pearson Correlation Coefficient -0.20118 0.4111 -0.81848 -0.81255 0.57198 -0.06975
R Standard Error 0.95953 0.831 0.3301 0.33977 0.67284 0.99513
t -0.20538 0.45097 -1.42457 -1.39398 0.69731 -0.06992
p-value 0.87104 0.73029 0.38964 0.39616 0.61235 0.95556
H0 (2%) accepted accepted accepted accepted accepted accepted
Pearson Correlation Coefficient 0.86354 0.99523 -0.80639 0.29199 0.96024 0.92269
R Standard Error 0.2543 0.00951 0.34973 0.91474 0.07794 0.14864
t 1.71243 10.20525 -1.36358 0.30529 3.43957 2.39323
p-value 0.33648 0.06218 0.40283 0.81137 0.18012 0.25197







































































































































































































approaches can offer insight into the impact of such strategies.18,19
Successfully implementing the principles of aid effectiveness (beyond the
few Paris Declaration indicators) necessitates many changes in behavior
and practice of donor and recipient countries. If the principles are not fully
implemented and the behaviors do not change, one cannot expect (only
partial) reform to yield useful results or favorable impacts on the system.
Rarely does anyone evaluate whether reforms have been implemented as
they were conceived, or whether they have produced the necessary
behavior changes.
We argue that results from aid effectiveness principles should be
measured at three levels.
1. Evaluate the Paris Declaration/IHPþ implementation processes as
well as their direct effect on changes in behavior for all stakeholders
(donors, government, service providers and so on). One can then
assess the extent to which the principles have been implemented, and
this increases understanding of how and why outcomes can be
improved. A mixed-method study design with a strong qualitative
component (multiple case studies) is likely to capture country-specific
features and help us to understand interactions in local contexts.
2. Assess how far donor support and Paris principles have contributed
to strengthening a health system, not only at the central (Ministry)
level, but also where the system meets those it is intended to serve.
Mounting evidence suggests that HSS is necessary to improve health
outcomes, including the performance of vertical programs.20 Such an
evaluation can be carried out with respect to health system pillars
(service delivery; health workforce; information; medical products,















































Figure 2: Behavioral view of the rationale of the Paris Declaration and IHPþ in the health sector.
Paul et al































































































































































































































































































	 HSSP-SP	 NAP	 IPL	




Total	expenditure	 $16,240,000	 $11,842,703	 $2,639,250	
Utilization	of	budget	 77.33%	 81.97%	 100%	
Total	DALYs	saved	(current	scenario)	 44,628	 35,325.19	 246,232.50	
Cost	per	DALY	saved	(current	scenario)	 $363.90	 $335.25	 $10.72	
Total	DALYs	saved	(target	scenario)	 107,616	 63,591	 464,208	








































































































































	Variable	 Total	score	 HSSP-SP	 NAP	 IPL	 Data	source	
Compliance	with	the	
Paris	Principles	





































































































































































































































	 HSSP-SP	 NAP	 IPL	
Programme	duration	(years)	 4.5	 6.5	 2.5	
Total	budget	 $21,000,000	 $14,446,916	 $2,639,250	
Total	expenditure	 $16,240,000	 $11,842,703	 $2,639,250	











































HSSP-SP	 87.2%	 100%	 88.89%	 100%	
NAP	 100%	 100%	 100%	 76.28%	





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Dimension	 Criteria	 Scoring	Description	 Score	









































































































































Dimension	 Criteria	 Scoring	Description	 Score	












































































































































































Dimension	 Criteria	 Scoring	Description	 Score	



























































































































































































Dimension	 Criteria	 Scoring	Description	 Score	
























































































































































Dimension	 Criteria	 Scoring	Description	 Score	


















































































































Dimension	 Criteria	 Scoring	Description	 Score	



















































































































Dimension	 Criteria	 Scoring	Description	 Score	











































































































































Dimension	 Criteria	 Scoring	Description	 Score	














































































Dimension	 Criteria	 Scoring	Description	 Score	





















































































































































Dimension	 Criteria	 Scoring	Description	 Score	














































Aid Effectiveness and Health Systems Strengthening in a Fragile State: A Comparative Analysis of 
Aid Management Modalities in Timor-Leste’s Health Sector 
 
INFORMATION SHEET AND CONSENT FORM FOR PARTICIPANTS 
 
Thank you for showing an interest in this project.  Please read this information sheet carefully before 
deciding whether or not to participate.  If you decide to participate we thank you.  If you decide not to 
take part there will be no disadvantage to you and we thank you for considering our request.   
 
What is the aim of the project? 
 
This project is undertaken as part of Doctoral research at the Department of Preventive and Social 
Medicine of the University of Otago, New Zealand. This project aims to analyze and compare the 
effects of three externally funded interventions in Timor-Leste’s health sector in terms of their project 
outcomes and impacts on the health system and tries to identify if different outcomes are correlated 
with internationally agreed aid effectiveness principles. 
 
Considering the specific fragile state context, intervention funding and management mechanisms, and 
their interactions with the health system, this research attempts to see what works for whom under 
what conditions with the following objectives— 
• Define aid effectiveness and develop an evaluation framework in the context of the health 
system of Timor-Leste 
• Identify and analyze different aid management modalities in Timor-Leste’s health sector in 
relation to their particular contexts, intervention plans and possible effect on the health system 
• Investigate for each aid management modality the extent of following aid effectiveness 
principles, interactions with health systems, and their short term and long term outcomes 
• Analyze the relationship between aid effectiveness principles, aid management modalities and 
project and health system outcomes and compare effectiveness of different health aid 
management modalities for their efficiency, transaction costs and development outcomes.   
 
What type of participants are being sought? 
 
We are involving key stakeholders from different sections of Timor-Leste’s health sector, 
development partners, implementers and beneficiaries in the process of this evaluation. Based on the 
role and relevant experience we are inviting a limited number of people to take part in this study and 
be part of a research reference group. 
 
Participant contribution will be duly acknowledged in the research report and publications and draft 
findings will be shared with the participants for their opinion before finalizing the report. Where 
applicable, participants will also be compensated for their local transportation costs incurred for taking 
part in this study. 
	 12	
    
What will participants be asked to do? 
 
Should you agree to take part in this project, you may be asked to: 
• Take part in two or three meetings of the stakeholders at different stages of the research. Each 
meeting may take between 60 minutes to 90 minutes. 
• Take part in an interview in a place and time according to your convenience and with a 
questionnaire shared with you before the interview. Completion of the questionnaire may take 
about 40 to 60 minutes of your time. 
• Occasionally give your comment and feedback by email or telephone on the areas of your 
knowledge, experience or expertise.  
 
Please be aware that you may decide not to take part in the project at any stage without any 
disadvantage to yourself of any kind. 
 
What data or information will be collected and what use will be made of it? 
 
This project will ask for information on and your opinions about activities and outcomes of three 
particular interventions such as the Global Fund funded National HIV/AIDS Program, AusAID-World 
Bank funded NHSSP-SP and USAID funded MCHIP. It will ask you to rate particular inputs, outputs 
and outcomes of those interventions according to your opinion. Your response will be recorded by 
written notes and if required by audio-taping. However, no individually identifying or personal 
questions will be asked. 
 
Information collected in this project will be used for scoring and evaluating the interventions for their 
comparative analysis. The information may be accessed by the researcher, researcher supervisors and 
the research reference group. There will be no commercial use of the data collected for this project. 
 
The data collected will be securely stored in computers with hardcopy and electronic file back-ups 
with limited access permission by the research team only. At the end of the project any personal 
information will be destroyed immediately except that, as required by the University's research policy, 
any raw data on which the results of the project depend will be retained in secure storage for five 
years, after which it will be destroyed. 
 
The research report and publications will reflect summary information and analysis and will not 
normally identify any person individually. On some occasions the readers of the research report might 
be able to identify an individual for an opinion, in such cases, on the Consent Form please indicate 
your preference of anonymity. Please be aware that should you wish we will make every attempt to 
preserve your anonymity. However, with your consent, there are some cases where it would be 
preferable to attribute contributions made to individual participants. It is absolutely up to you which of 
these options you prefer. The results of the project may be published and will be available in the 
University of Otago Library (Dunedin, New Zealand). 
 
Along with a structured questionnaire, this project may also involve an open-questioning technique. 
The general line of questioning includes your rating of particular result indicators and associated 
contextual information to interpret your rating. The precise nature of the questions which will be asked 
have not been determined in advance, but will depend on the way in which the interview develops. 
 
In the event that the line of questioning does develop in such a way that you feel hesitant or 
uncomfortable you are reminded of your right to decline to answer any particular question(s) and also 
that you may withdraw from the project at any stage without any disadvantage to yourself of any kind. 
The draft study report will be shared with you for your opinion and you will be given chance to review 
and correct any opinion, which can be attributed to you, appears there. 
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This proposal has been reviewed and approved by the Department of Preventive and Social Medicine of the 
University of Otago. This has also been submitted for review and approval by the Research Ethics Committee 
of the Ministry of Health of Timor-Leste. 
  
 
Can participants change their mind and withdraw from the project? 
 
Again, please be assured that you may withdraw from participation in the project at any time and 
without any disadvantage to yourself of any kind. 
 
What if participants have any questions? 
If you have any questions about our project, either now or in the future, please feel free to contact 
either: 
Hasibul Haque  and/or    Prof. Robin Gauld 
Department of Preventive and Social Medicine  Department of Preventive and Social 
Medicine 
Telephone: +64 3 479 4011    Telephone: +64 3 479 8632 
Email: hasibul.haque@yahoo.com    Email: robin.gauld@otago.ac.nz  
 
This study has been approved by the Department stated above. If you have any concerns about the 
ethical conduct of the research you may contact the Committee through the Human Ethics Committee 
Administrator (ph 03 479-8256). Any issues you raise will be treated in confidence and investigated 
and you will be informed of the outcome. 
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I have read the Information Sheet concerning this project and understand what it is about.  All my 
questions have been answered to my satisfaction.  I understand that I am free to request further 
information at any stage. 
 
I know that: 
 
1. My participation in the project is entirely voluntary; 
 
2. I am free to withdraw from the project at any time without any disadvantage; 
 
3. Personal identifying information recorded in emails and audio-tapes will be destroyed at the 
conclusion of the project but any raw data on which the results of the project depend will be 
retained in secure storage for at least five years; 
 
4. This project may involve an open-questioning technique. The general line of questioning 
includes rating of result indicators of particular interventions and contextual information to 
interpret the rating.  The precise nature of the questions which will be asked have not been 
determined in advance, but will depend on the way in which the interview develops and 
that in the event that the line of questioning develops in such a way that I feel hesitant or 
uncomfortable I may decline to answer any particular question(s) and/or may withdraw 
from the project without any disadvantage of any kind; 
 
5. There will be no commercial use of data collected in this project; 
 
6. The results of the project may be published and available in the University of Otago Library 
(Dunedin, New Zealand) but every attempt will be made to preserve my anonymity. 
 
 I wish to keep complete anonymity of my identity in the research reports. (Please tick if applicable 
to you) 
 
I agree to take part in this project. 
 
 
.............................................................................    ............................... 














Manager, Academic Committees, Mr Gary Witte
D12/240
Professor R Gauld
Department of Preventive and Social Medicine
Dunedin School of Medicine
Dear Professor Gauld,
I am again writing to you concerning your proposal entitled “Aid Effectiveness and Health
Systems Strengthening in a Fragile State: a Comparative Analysis of Aid Management
Modalities in Timor-Leste’s Health Sector”, Ethics Committee reference number D12/240.
Thank you for your comprehensive response to our letter. We acknowledge that you have
provided us with the following documentation: a letter outlining the documentation and
assurances held by the Department relating to Hasibul Haque’s travel arrangements,
insurance details and medical preparations; the NZ Government travel advisory for
Timor-Leste and the WHO’s health information for travellers; and documentation from
Timor-Leste governmental authorities providing approval for the research project and Hasibul
Haque’s special stay authorisation. We note your advice regarding Hasibul Haque’s
experience working for the UN in Timor-Leste; and the amended Information Sheet and
Consent Form which gives participants an estimation of the time involved in participating in
the questionnaire and focus group.







 c.c. Professor J L Connor  Head  Department of Preventive and Social Medicine 	
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Annex	5:	List	of	unpublished	project	documents	used	as	
information	sources	
	
A.	HSSP-SP:	
1. Final	minutes	of	Timor-Leste	health	donor	harmonization	meeting,	Date	and	
Time:	28	July	2011,	9.30	–	10:30	
2. Dewdney,	J.,	Martins,	J.,	Asante,	A.,	&	Zwi,	A.	(2009).	Strengthening	human	
resources	for	health	in	Timor-Leste:	Progress,	challenges	and	ways	forward.	
Mission	report	submitted	to	the	Ministry	of	Health	and	World	Bank.	Dili	
3. MoH	and	SIHSIP.	(2007).	Report	on	the	Current	and	Proposed	Timor-Leste	MOH	
Health	Centre	and	Health	Post	Professional	Staffing	Establishments.	
4. Kong,	F.	(2010).	Report	of	the	Pharmaceutical	Sector	in	Timor-Leste:	
Contribution	Paper	to	the	Mid-term	Review	of	the	Health	Sector	in	Timor-Leste	
July	2010.	
5. World	Bank.	(2013).	Project	Paper	On	A	Proposed	Additional	Financing	And	
1. Project	Restructuring	In	The	Amount	Of	Us$	17.7	Million	To	The	
2. Democratic	Republic	Of	Timor-Leste	For	The	Health	Sector	Strategic	Plan	
Support	Project	
6. World	Bank	and	MoH.	(2012).	Major	related	projects	financed	by	AusAID,	EU,	WB	
and/or	other	agencies.	Timor-Leste:		NHSSP-SP	
7. World	Bank.	(2011).	Terms	of	Reference:	Joint	Partner	Design	Mission	for	Timor-
Leste	Health	Sector:	MoH,	AusAID,	EC	and	World	Bank.	11	–	30	May	2011	
8. World	Bank.	(2013).	Implementation	Status	&	Results:	Timor-Leste	Health	Sector	
Strategic	Plan	Support	Project	(P104794).	August		
9. Strategic	Planning	Agreement	for	Development	between	the	Government	of	
Timor-Leste	and	the	Government	of	Australia.	November	2011	
10. World	Bank.	(2011).	Results	Framework	and	Monitoring	(version	2	June	2011)	
3. Timor-Leste:		National	Health	Sector	Strategic	Plan	Support	Program	(NHSSP-SP)	
11. World	Bank.	(2007).	Project	Information	Document	(PID):	Concept	Stage.	Report	
No.:		AB2844	
12. World	Bank.	(2007).	Integrated	Safeguards	Data	Sheet:	Concept	Stage.	Report	
No.:		AC2734	
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13. World	Bank.	(2007).	Project	Appraisal	Document	On	A	Proposed	IDA	Grant	in	the	
Amount	of	SDR	640,000	(US$1	million	equivalent)	to	the	Democratic	Republic	of	
Timor-Leste	for	a	Health	Sector	Strategic	Plan	Support	Project.	Report	No:	
40747-TP.	November	14,	2007	
14. Financing	Agreement	(Health	Sector	Strategic	Plan	Support	Project)	between	
Democratic	Republic	of	Timor-Leste	and	International	Development	Association	
Dated	April	16,	2008	
15. MoH.	(2011).	Health	Sector	Strategic	Plan	-	Support	Project	(HSSP-SP)	
Procurement	Plan	(PP).	1st	revision	28	January	2009;	2nd	Revision	30	January	
2010;	3rd	revision	8	February	2011,	Grant	No.	H	343-TP,	HSSP-SP	
16. World	Bank.	(2012).		Restructuring	Paper	on	a	Proposed	Project	Restructuring	of	
Timor-Leste	Health	Sector	Strategic	Plan	Support	Project.	Report	No.	67307	v1	
17. European	Union.	(2012).	Action	Fiche	for	Timor-Leste.	Support	to	Health	Sector	/	
FED/2011/022-743	
18. MoH.	(2011).	Health	Sector	Mid	Term	Review	2010.	
19. AusAID.	(2007).	Report	on	Quality	at	Entry	and	Next	Steps	to	Complete	Design	
for	East	Timor	Health	Sector	Strategic	Plan	Support	Program	
20. World	Bank.	(2012).	Timor-Leste	Health	Sector	Strategic	Plan	Support	Project:	
Results	Framework	
21. World	Bank	and	Government	of	Timor-Leste.		(2013).	Agreement	Providing	for	
the	Amendment	and	Restatement	of	the	Financing	Agreement	(National	Health	
Sector	Strategic	Plan	Support	Project)	between	Democratic	Republic	of	Timor-
Leste	and	International	Development	Association.	Dated	25	April	2013	
22. World	Bank.	(2011).	Implementation	Status	&	Results.	Timor-Leste	Health	Sector	
Strategic	Plan	Support	Project	(P104794).	January		
23. World	Bank.	(2012).	Implementation	Status	&	Results.	Timor-Leste	Health	Sector	
Strategic	Plan	Support	Project	(P104794).	January	
24. World	Bank.	(2012).	Implementation	Status	&	Results.	Timor-Leste	Health	Sector	
Strategic	Plan	Support	Project	(P104794).	November	
25. World	Bank.	(2013).	Implementation	Status	&	Results.	Timor-Leste	Health	Sector	
Strategic	Plan	Support	Project	(P104794).	May	
26. World	Bank.	(2013).	Implementation	Status	&	Results.	Timor-Leste	Health	Sector	
Strategic	Plan	Support	Project	(P104794).	August	
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27. AusAID	and	World	Bank.	(2008).	Trust	Fund	Administration	Agreement	between	
the	Commonwealth	of	Australia,	the	Australian	Agency	for	International	
Development,	and	the	International	Bank	for	Reconstruction	and	Development	
and	International	Development	Association	concerning	the	Multi-Donor	Trust	
Fund	for	the	Health	Sector	Strategic	Plan—Support	Project	in	Timor-Leste	(TF	
No.	070953)	(AusAID	Agreement	No.	44827)	
28. World	Bank.	(2010).	Progress	Report	June	2008	–	June	2009:	Health	Sector	
Strategic	Plan	-	Support	Project	(HSSP-SP)	
29. World	Bank	and	MoH.	(2013).	Results	Framework	for	Project	Development	
Objectives	Indicataors:	Timor-Leste	National	Health	Sector	Strategic	Plan—
Support	Project	(NHSSP-SP)	
30. Deloitte.	(2009).	Annual	Audit	Report	for	Timor-Leste	Health	Sector	Strategic	
Plan	Support	Project	(HSSP-SP)	
31. Deloitte.	(2010).	Annual	Audit	Report	for	Timor-Leste	Health	Sector	Strategic	
Plan	Support	Project	(HSSP-SP)	
32. Deloitte.	(2011).	Annual	Audit	Report	for	Timor-Leste	Health	Sector	Strategic	
Plan	Support	Project	(HSSP-SP)	
33. Deloitte.	(2012).	Annual	Audit	Report	for	Timor-Leste	Health	Sector	Strategic	
Plan	Support	Project	(HSSP-SP)	
34. Deloitte.	(2013).	Annual	Audit	Report	for	Timor-Leste	Health	Sector	Strategic	
Plan	Support	Project	(HSSP-SP)	(Draft)	
35. MoH.	(2013).	Asset	Register	for	Timor-Leste	Health	Sector	Strategic	Plan	Support	
Project	(HSSP-SP)	
36. MoH.	(2013).	Staff	List	for	Timor-Leste	Health	Sector	Strategic	Plan	Support	
Project	(HSSP-SP)	
	
B.	NAP:	
1. MoH.	(2013).	Asset	Register	for	National	HIV/AIDS	Programme	of	Timor-Leste	
2. MoH.	(2013).	Staff	List	for	National	HIV/AIDS	Programme	of	Timor-Leste	
3. Global	Fund.	(2012).	Development	Partner	Handover	Report	2012	to	National	
Directorate	of	Aid	Effectiveness	of	Timor-Leste.	
4. Global	Fund.	(2012).	Timor-Leste	TLS-H-MOH:	Grant	Performance	Report.	
External	Prinit	Version	Last	Updated	on	5	November	2012.	
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5. Global	Fund.	(2014).	Timor-Leste	TLS-H-MOH:	Grant	Performance	Report.	
External	Prinit	Version	Last	Updated	on	18	July	2014.	
6. Global	Fund.	(2014).	Timor-Leste	TLS-H-MOH:	Grant	Performance	Report.	
External	Prinit	Version	Last	Updated	on	4	September	2014.	
7. MoH.	(2013).	Timor-Leste	TLS-H-MOH:	Enhanced	Financial	Report	for	Jan-Dec	
2012	
8. Global	Fund.	(2013).	Timor-Leste	TLS-H-MOH:	Grant	Performance	Report.	
External	Prinit	Version	Last	Updated	on	12	December	2013.	
9. Global	Fund.	(2012).	Timor-Leste	TMP-503-G03-H:	Grant	Performance	Report.	
External	Prinit	Version	Last	Updated	on	8	June	2012.	
10. Global	Fund.	(2010).	Timor-Leste	TMP-503-G03-H:	Grant	Scorecard	
11. MoH.	(2012).	Timor-Leste	TLS-H-MOH:	Enhanced	Financial	Report	for	Jan-Dec	
2011	
12. Global	Fund	and	MoH	(2007).	Grant	Agreement	for	Enhanced	Comprehensive	
Response	to	HIV	and	AIDS	in	Timor-Leste	TMP-503-G03-H	
13. Global	Fund	and	MoH	(2012).	Grant	Agreement	for	Enhanced	Comprehensive	
Response	to	HIV/AIDS	and	STI	in	Timor-Leste	TLS-H-MOH	
14. MoH.	(2011).	National	Monitoring	and	Evaluation	Plan	for	HIV/AIDS	and	STI.	Dili:	
National	HIV/AIDS	and	STI	Programme	of	Timor-Leste	
	
IPL:	
1. GAVI	Alliance	Annual	Progress	Report	2012.	Submitted	by	the	Government	of	
Timor-Leste	
2. UNICEF	Annual	Report	2012	for	Timor-Leste	
3. IPL.	(2011).	Immunizasaun	Proteje	Labarik	Quarter	report:	April-June	2011	
4. IPL.	(2011).	Immunizasaun	Proteje	Labarik	Quarter	report:	July-September	2011	
5. IPL.	(2012).	Immunizasaun	Proteje	Labarik	Quarter	report:	October-December	
2011	
6. IPL.	(2012).	Immunizasaun	Proteje	Labarik	Quarter	report:	January-March	2012	
7. IPL.	(2012).	Immunizasaun	Proteje	Labarik	Quarter	report:	Apri-June	2012	
8. IPL.	(2012).	Immunizasaun	Proteje	Labarik	Quarter	report:	July-September	2012	
9. IPL.	(2013).	Immunizasaun	Proteje	Labarik	Quarter	report:	October-December	
2012	
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10. IPL.	(2013).	Immunizasaun	Proteje	Labarik	Quarter	report:	January-March	2013	
11. IPL.	(2011).	PMP	data	compilation	sheet	and	quarterly	reporting	format	(Results	
Framework)	
12. IPL.	(2011).	Project	Monitoring	and	Evaluation	Plan	
13. IPL.	(2011).	Annual	report:	Fiscal	year	2011	
14. IPL.	(2013).	Project	Asset	Inventory	Report	as	at	28	February	2013	
15. IPL.	(2013).	Inventory	Report:	Durable	Expendable	Equipment	(Exp	<$500)	as	at	
31	March	2013	
16. IPL.	(2012).	Immunizasaun	Proteje	Labarik:	Baseline	Assessment	Report	
17. IPL.	(2013).	Immunizasaun	Proteje	Labarik	Expense	Report	for	2012	Submitted	
to	the	Ministry	of	Health	
18. USAID	and	Government	of	Timor-Leste.	(2010).	USAID	Grant	Agreement	No.	472-
004.	Assistance	Agreement	between	the	United	States	of	America,	acting	through	
the	United	States	Agency	for	International	Development	(USAID)	and	the	
Government	of	the	Democratic	Republic	of	Timor-Leste.	Dated	22	September	
2010.	
19. IPL.	(2013).	Immunizasaun	Proteje	Labarik.	Final	Program	Report:	April	2011	to	
December	2013	
20. JSI	Timor-Leste.	(2013).	Staff	List	for	Immunizasaun	Proteje	Labarik	(IPL)	
21. MCHIP.	(2011).	Maternal	and	Child	Health	Integrated	Program	(MCHIP):	Mid	
Term	Evaluation	Report	
	
	
	
	
	
